Therapeutic potential of toleragens in the management of antiphospholipid syndrome

BioDrugs

Volumn 18, Issue 5, 2004, Pages 297-305

  Cockerill, Keith A ^a,b   Iverson, G Michael ^a   Jones, David S ^a   Linnik, Matthew D ^a  

^a La Jolla Pharmaceutical Company   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL TOLERAGEN; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOLOGIC AGENT; LJP 1082; LUPUS ANTICOAGULANT; PROTEIN C; THROMBOPLASTIN; UNCLASSIFIED DRUG; WARFARIN;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; HUMAN; IMMUNOLOGICAL TOLERANCE; MICROANGIOPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; GLYCOPROTEINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHODS; MODELS, BIOLOGICAL; ORGANIC CHEMICALS; POLYETHYLENE GLYCOLS;

EID: 6044256196     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418050-00002     Document Type: Review

References (107)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11
2. Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment. Ann Med Interne (Paris) 1996; 147 Suppl. 1: 24-7
3. Muir KW, Squire IB, Alwan W, et al. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994; 344: 452-6
4. Italian Registry of Antiphospholipid Antibodies (1R-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematologica 1993; 78: 313-8
5. Hamsten A, Norberg R, Bjorkholm M, et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; I: 113-6
6. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 366-74
7. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68: 353-65
8. Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990; 17: 1292-8
9. Koike T, Tsutsumi A. Pulmonary hypertension and the antiphospholipid syndrome [letter]. Intern Med 1995; 34: 938
10. Kunieda T. Antiphospholipid syndrome and pulmonary hypertension. Intern Med 1996; 35: 842-3
11. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80: 355-77
12. Au A, O'Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment. Clin Exp Ophthalmol 2004; 32: 87-100
13. Cuadrado MJ, Lopez-Pedrera C. Antiphospholipid syndrome. Clin Exp Med 2003; 3: 129-39
14. Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50: 1028-39
15. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 2003; 48: 3320-7
16. Fakhouri F, Noel LH, Zuber J, et al. The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis 2003; 41: 1205-11
17. Katzav A, Chapman J, Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 2003; 12: 903-7
18. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment: committee consensus report. Lupus 2003; 12: 518-23
19. Meroni PL, Moia M, Derksen RH, et al. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus 2003; 12: 504-7
20. Paran D, Fireman E, Elkayam O. Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome. Autoimmun Rev 2004; 3: 70-5
21. Sastre-Garriga J, Montalban X. APS and the brain. Lupus 2003; 12: 877-82
22. Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12: 524-9
23. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-8
24. Derksen RH, de Groot PG, Kater L, et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689-92
25. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8
26. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118: 511-20
27. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7
28. McNeil HP, Simpson RJ, Chesterman CN, et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 4120-4
29. Matsuura E, Igarashi Y, Fujimoto M, et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8
30. Bevers EM, Galli M, Barbui T, et al. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32
31. Arvieux J, Darnige L, Caron C, et al. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 1120-5
32. Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 2618-25
33. Matsuda J, Saitoh N, Gohchi K, et al. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 1994; 47: 56-8
34. Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol 2000; 108: 871-5
35. Petri M. Classification and epidemiology of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, et al., editors. The antiphospholipid syndrome II. Amsterdam: Elsevier, 2002: 11-20
36. Tanne D, Levine SR, Kittner SJ. Epidemiology of antiphospholipid antibodies and vascular disease. In: Levine SR, Brey RL, editors. Clinical approach to antiphospholipid antibodies. Boston (MA): Butterworth Heinemann, 2000: 1-18
37. Hess DC, Krauss J, Adams RJ, et al. Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology 1991; 41 (4): 525-8
38. The Antiphospholipid Antibodies in Stroke Study Group (APASS). Clinical, radiological, and pathological aspects of cerebrovascular disease associated with antiphospholipid antibodies. Stroke 1993; 24 (12 Suppl.): I120-3
39. Eschwege V, Peynaud-Debayle E, Wolf M, et al. Prevalence of antiphospholipid-related antibodies in unselected patients with history of venous thrombosis. Blood Coagul Fibrinolysis 1998; 9 (5): 429-34
40. Zielinska J, Ryglewicz D, Wierzchowska E, et al. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol Res 1999; 21 (7): 653-7
41. Tuhrim S, Rand JH, Wu XX, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999; 30: 1561-5
42. Balasch J, Creus M, Fabregues F, et al. Antiphospholipid antibodies and human reproductive failure. Hum Reprod 1996; 11 (10): 2310-5
43. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996; 66 (4): 540-6
44. Branch DW, Silver R, Pierangeli S, et al. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997; 89 (4): 549-55
45. Kutteh WH. Antiphospholipid antibodies and reproduction. J Reprod Immunol 1997; 35 (2): 151-71
46. Buchanan RR, Wardlaw JR, Riglar AG, et al. Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme frust disease. J Rheumatol 1989; 16 (6): 757-61
47. Cervera R, Font J, Lopez-Soto A, et al. Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients. Ann Rheum Dis 1990; 49 (2): 109-13
48. Worrall JG, Snaith ML, Batchelor JR, et al. SLE: a rheumatological view: analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q J Med 1990; 74: 319-30
49. Galli M, Luciani D, Bertolini G, et al. Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23
50. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002
51. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy: Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332-8
52. Petri M, Rheinschmidt M, Whiting-O'Keefe Q, et al. The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med 1987; 106: 524-31
53. Derksen RH, Bouma BN, Kater L. The prevalence and clinical associations of the lupus anticoagulant in systemic lupus erythematosus. Scand J Rheumatol 1987; 16: 185-92
54. Wahl DG, Guillemin F, De Maistre E, et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15-22
55. Wahl DG, Guillemin F, De Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: a meta-analysis. Lupus 1997; 6: 467-73
56. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-7
57. Brey RL, Abbott RD, Curb JD, et al. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 2001; 32: 1701-6
58. Kornberg A, Blank M, Kaufman S, et al. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 1328-32
59. Reverter JC, Tassies D, Font J, et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 1996; 16: 1319-26
60. Amengual O, Atsumi T, Khamashta MA, et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-81
61. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40: 834-41
62. Dobado-Berrios PM, Lopez-Pedrera C, Velasco F, et al. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999; 82: 1578-82
63. Salemink I, Blezer R, Willems GM, et al. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000; 84: 653-6
64. Borrell M, Sala N, de Castellarnau C, et al. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68: 268-72
65. Cariou R, Tobelem G, Soria C, et al. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314: 1193-4
66. Cariou R, Tobelem G, Bellucci S, et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells: inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988; 60: 54-8
67. Malia RG, Kitchen S, Greaves M, et al. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-7
68. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-32
69. Matsuda J, Gotoh M, Gohchi K, et al. Resistance to activated protein C activity of an anti-beta 2-glycoprotein I antibody in the presence of beta 2-glycoprotein I. Br J Haematol 1995; 90: 204-6
70. Oosting JD, Preissner KT, Derksen RH, et al. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993; 85: 761-8
71. Pengo V, Biasiolo A, Brocco T, et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75: 721-4
72. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Deleze M, et al. Acquired protein C deficiency in a patient with primary antiphospholipid syndrome: relationship to reactivity of anticardiolipin antibody with thrombomodulin. J Rheumatol 1989; 16: 381-3
73. Lutters BC, Derksen RH, Tekelenburg WL, et al. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278: 33831-8
74. Shi T, Iverson GM, Qi JC, et al. β2glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped β2glycoprotein I. Proc Natl Acad Sci U S A 2004; 101: 3939-44
75. Rand JH, Wu XX, Andree HA, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood 1998; 92: 1652-60
76. Hanly JG, Smith SA. Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol 2000; 120: 537-43
77. Willems GM, Janssen MP, Comfurius P, et al. Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes. Biochemistry 2000; 39: 1982-9
78. Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67: 649-53
79. Yasuda S, Tsutsumi A, Chiba H, et al. Beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000; 152: 337-46
80. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A 1993; 90: 2141-5
81. Horbach DA, van Oort E, Lisman T, et al. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999; 81: 87-95
82. Bouma B, de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-74
83. Schwarzenbacher R, Zeth K, Diederichs K, et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228-39
84. Hammel M, Kriechbaum M, Gries A, et al. Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. J Mol Biol 2002; 321: 85-97
85. Matsuura E, Igarashi Y, Fujimoto M, et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885-91
86. Ichikawa K, Khamashta MA, Koike T, et al. Beta 2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453-61
87. Koike T, Tsutsumi A, Ichikawa K, et al. Antigenic specificity of the "anticardiolipin" antibodies. Blood 1995; 85: 2277-80
88. Matsuura E, Igarashi Y, Yasuda T, et al. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62
89. Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34
90. Roubey RA, Eisenberg RA, Harper MF, et al. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid: importance of Ag density and bivalent binding. J Immunol 1995; 154: 954-60
91. Sheng Y, Kandiah DA, Krilis SA. Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity. J Immunol 1998; 161: 2038-43
92. Arvieux J, Regnault V, Hachulla E, et al. Heterogeneity and immunochemical properties of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 1998; 80: 393-8
93. Chamley LW, Duncalf AM, Konarkowska B, et al. Conformationally altered beta 2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. Clin Exp Immunol 1999; 115: 571-6
94. Forastiero RR, Martinuzzo ME, Kordich LC, et al. Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996; 75: 717-20
95. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998; 95: 15542-6
96. Tincani A, Spatola L, Prati E, et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol 1996; 157: 5732-8
97. Iverson GM, Matsuura E, Victoria EJ, et al. The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA. J Autoimmun 2002; 18: 289-97
98. Giles IP, Isenberg DA, Latchman DS, et al. How do antiphospholipid antibodies bind beta2-glycoprotein I? Arthritis Rheum 2003; 48: 2111-21
99. McNeeley PA, Dlott JS, Furie RA, et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost 2001; 86: 590-5
100. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097-103
101. Jones DA, Branks MJ, Campbell MA, et al. Multivalent poly(ethylene glycol)-containing conjugates for in vivo antibody suppression. Bioconjug Chem 2003; 14 (6): 1067-76
102. Cockerill KA, Smith E, Jones DS, et al. In vivo characterization of bioconjugate B cell toleragens with specificity for autoantibodies in antiphospholipid syndrome. Int Immunopharmacol 2003; 3: 1667-75
103. Abetimus: Abetimus sodium, LJP 394. BioDrugs 2003; 17 (3): 212-5
104. Abetimus sodium. Drugs of the Future 2001; 26 (7): 633-8
105. Weisman MH, Bluestein HG, Berner CM, et al. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997; 24 (2): 314-8
106. Furie RA, Cash JM, Cronin ME, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001; 28 (2): 257-65
107. Wallace DJ. Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs 2001; 10 (1): 111-7